萨吉梅生物科学

最新新闻

• 评级变动
  JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• A Quick Look at Today's Ratings for Sagimet Biosciences(SGMT.US), With a Forecast Between $25.1 to $56
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Goldman Sachs Initiates Sagimet Biosciences(SGMT.US) With Sell Rating, Announces Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT) and Jade Biosciences (JBIO)
  TipRanks · 2026/10/1
• H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT) and Liquidia Technologies (LQDA)
  TipRanks · 2026/10/1
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)
  TipRanks · 2026/9/28
• 评级变动
  Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy From Cantor Fitzgerald
  TipRanks · 2026/10/1
• 评级变动
  Leerink Partners Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Sagimet Biosciences, Inc. Class A (SGMT)
  TipRanks · 2026/10/1
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)
  TipRanks · 2026/10/1
• Analysts Are Bullish on Top Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Sagimet Biosciences, Inc. Class A (SGMT)
  TipRanks · 2026/10/5
• 评级变动
  A Quick Look at Today's Ratings for Sagimet Biosciences(SGMT.US), With a Forecast Between $25 to $49
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• Goldman Sachs Maintains Sagimet Biosciences(SGMT.US) With Sell Rating, Maintains Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Guggenheim Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Sagimet Biosciences, Inc. Class A (SGMT)
  TipRanks · 2026/8/25
• 评级变动
  Barclays Upgrades Sagimet Biosciences(SGMT.US) to Buy Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Cantor Fitzgerald Initiates Sagimet Biosciences(SGMT.US) With Buy Rating, Announces Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Oppenheimer Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $38
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Oppenheimer Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/8/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。